Tag:
Paladin Labs
Latest Headlines
Latest Headlines
Paladin acquiring Labopharm in $20M deal
Paladin Labs has struck a deal to buy Labopharm in a deal that values the biotech at a bit more than $20 million. Paladin is paying 28.5 cents a share, a significant premium over the bargain basement
Paladin makes hostile bid for Afexa
Paladin Labs is offering a modest premium in a hostile bid to take over Afexa Life Sciences in a deal that values the company at $56.7 million. Investors in Afexa, which makes the flu drug COLD-FX,
Isotechnika nabs $11M in voclosporin pact
Canada's Paladin Labs has struck a deal on the development and commercialization of voclosporin, a next-generation calcineurin inhibitor that is Isotechnika's lead drug program. Voclosporin is being
